ATE435234T1 - Hetero-oligomere hiv-hüllproteine - Google Patents

Hetero-oligomere hiv-hüllproteine

Info

Publication number
ATE435234T1
ATE435234T1 AT05855755T AT05855755T ATE435234T1 AT E435234 T1 ATE435234 T1 AT E435234T1 AT 05855755 T AT05855755 T AT 05855755T AT 05855755 T AT05855755 T AT 05855755T AT E435234 T1 ATE435234 T1 AT E435234T1
Authority
AT
Austria
Prior art keywords
hiv
different
heterotrimer
env glycoprotein
hiv envelope
Prior art date
Application number
AT05855755T
Other languages
English (en)
Inventor
Leonidas Stamatatos
Original Assignee
Seattle Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Res Inst filed Critical Seattle Biomedical Res Inst
Application granted granted Critical
Publication of ATE435234T1 publication Critical patent/ATE435234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05855755T 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine ATE435234T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032904P 2004-12-29 2004-12-29
PCT/US2005/047244 WO2006071933A2 (en) 2004-12-29 2005-12-28 Hetero-oligomeric hiv envelope proteins

Publications (1)

Publication Number Publication Date
ATE435234T1 true ATE435234T1 (de) 2009-07-15

Family

ID=36615506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05855755T ATE435234T1 (de) 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine

Country Status (9)

Country Link
US (1) US20080248063A1 (de)
EP (2) EP2088155A1 (de)
CN (1) CN101094862A (de)
AT (1) ATE435234T1 (de)
DE (1) DE602005015256D1 (de)
DK (1) DK1831247T3 (de)
ES (1) ES2328507T3 (de)
WO (1) WO2006071933A2 (de)
ZA (1) ZA200706186B (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE416795A (de) 1936-08-07 1936-08-31
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6716429B1 (en) 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
EP1214333A4 (de) 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc STABILISIERTE LöSLICHE GLYKOPROTEINTRIMERE
EP1246607B1 (de) 1999-12-30 2007-06-27 Dana-Farber Cancer Institute, Inc. Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
AU2002335709B8 (en) * 2001-09-06 2008-12-18 Cornell Research Foundation, Inc. Human Immunodeficiency Virus Envelope Clycoprotein Mutants and Uses Thereof

Also Published As

Publication number Publication date
DK1831247T3 (da) 2009-10-12
CN101094862A (zh) 2007-12-26
EP1831247B1 (de) 2009-07-01
US20080248063A1 (en) 2008-10-09
EP1831247A2 (de) 2007-09-12
ZA200706186B (en) 2008-06-25
HK1107998A1 (en) 2008-04-25
WO2006071933A2 (en) 2006-07-06
WO2006071933A3 (en) 2007-02-15
DE602005015256D1 (de) 2009-08-13
EP2088155A1 (de) 2009-08-12
ES2328507T3 (es) 2009-11-13

Similar Documents

Publication Publication Date Title
Yang et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
He et al. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors
DK1402015T3 (da) Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
JP2019501882A5 (de)
BRPI0514108A (pt) polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos
WO2008063331A3 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
Xiong et al. A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus
ATE308558T1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
DK1831247T3 (da) Hetero-oligomere HIV-kappeproteiner
JP2006503849A5 (de)
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
WO2004108886A3 (en) Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein
Billington et al. Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
WO2008144700A3 (en) Simian t-cell lymphotropic virus type 3 west african subtype d
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
TH87273A (th) วัคซีน
BR9715035A (pt) Processo para produção da proteìna hìbrida
CU23471A1 (es) Péptido quimérico de la proteína de la transmembrana (gp41) y la proteína de la envoltura (gp120) del vih-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1831247

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1831247

Country of ref document: EP